# Phase 2 Cognitive Dysfunction trials recruiting: 55 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 55 trials in phase 2 for Cognitive Dysfunction that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Cognitive Dysfunction trials: 55 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/cognitive-dysfunction

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 55
- Recruiting or not yet: 55
- Read on: November 19, 2026

## Trials

The 25 newest of 55, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07882901 | Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Mild Cognitive Impairment (MCI) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882901) |
| October 14, 2026 | NCT07873463 | Flutemetamol F 18 Injection Formulation Comparison | GE Healthcare | Phase 2 | Recruiting | Cognitive Dysfunction | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873463) |
| September 4, 2026 | NCT07804498 | CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium | University of Milano Bicocca | Phase 2 | Recruiting | Cognitive Decline, Delirium | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804498) |
| August 11, 2026 | NCT07757542 | Safety Assessment of H2 Inhalation in Patients With Mild Cognitive Impairment | University of Ostrava | Phase 2 | Recruiting | Mild Cognitive Impairment (MCI) | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757542) |
| August 10, 2026 | NCT07756294 | Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease | Wake Forest University Health Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756294) |
| August 3, 2026 | NCT07741071 | N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease | Haukeland University Hospital | Phase 2 | Recruiting | Alzheimer Disease (AD) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741071) |
| July 10, 2026 | NCT07695090 | Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients | Qanatpharma AG | Phase 2 | Recruiting | Heart Failure With Reduced Ejection Fraction | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695090) |
| May 15, 2026 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Eli Lilly and Company | Phase 2 | Recruiting | Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589595) |
| May 12, 2026 | NCT07579884 | To Evaluate the Safety and Efficacy of RP902 Tablets | Risen (Suzhou) Pharma Tech Co., Ltd. | Phase 2 | Recruiting | Mild Cognitive Impairment (MCI) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579884) |
| April 28, 2026 | NCT07553338 | Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease | Weill Medical College of Cornell University | Phase 2 | Recruiting | Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553338) |
| April 6, 2026 | NCT07512362 | Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512362) |
| February 24, 2026 | NCT07430046 | Repurposing Mirtazapine in Rett Syndrome | University of Trieste | Phase 2 | Recruiting | RETT Syndrome With Proven MECP2 Mutation | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430046) |
| February 17, 2026 | NCT07414537 | Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator | VA Office of Research and Development | Phase 2 | Not yet recruiting | Cognition, Brain Injuries, Stress Disorders, Post-Traumatic | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414537) |
| February 6, 2026 | NCT07392723 | ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392723) |
| January 14, 2026 | NCT07338682 | Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients | German University in Cairo | Phase 2 | Recruiting | Cognition Disorders in Old Age, Cognitive and Behavioral Impairment | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07338682) |
| January 12, 2026 | NCT07334912 | AEF0217 in Participants With Down Syndrome | Aelis Farma | Phase 2 | Recruiting | Down Syndrome (Trisomy 21) | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334912) |
| January 5, 2026 | NCT07316153 | Deep Sleep in Older Adults | Proactive Life Inc | Phase 2 | Recruiting | Insomnia, Insomnia Chronic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316153) |
| November 19, 2025 | NCT07236190 | Biomarker-based Trial of NPC-1 for Alzheimer's Pathology | Massachusetts General Hospital | Phase 2 | Recruiting | Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236190) |
| October 20, 2025 | NCT07217912 | Daridorexant to Prevent Post-cardiotomy Delirium | University of Rochester | Phase 2 | Recruiting | Postoperative Cognitive Decline, Postoperative Delirium | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217912) |
| October 8, 2025 | NCT07213349 | Daridorexant for Alzheimer Disease Prevention | Douglas Mental Health University Institute | Phase 2 | Recruiting | Alzheimer Disease (AD) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213349) |
| September 25, 2025 | NCT07192913 | Glymphatic Function TMS Study | University of Arizona | Phase 2 | Not yet recruiting | Mild Cognitive Impairment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192913) |
| June 18, 2025 | NCT07027072 | Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia... | NeuroBiogen Co., Ltd | Phase 2 | Recruiting | Mild Cognitive Impairment (MCI), Mild Dementia, Alzheimer&#39;s Disease | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027072) |
| June 10, 2025 | NCT07012993 | Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012993) |
| May 4, 2025 | NCT06957418 | Alzheimer's Tau Platform: Master Protocol | Sponsor not shown (see the record) | Phase 2 | Recruiting | Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957418) |
| March 7, 2025 | NCT06862960 | Ozanimod in Patients With Alzheimer's Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alzheimer Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06862960) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| St. Joseph's Hospital and Medical Center, Phoenix | 2 |
| Johns Hopkins University | 2 |
| Brigham and Women's Hospital | 2 |
| Massachusetts General Hospital | 2 |
| Columbia University | 2 |
| University of Alberta | 1 |
| University of Arizona | 1 |
| University of Trieste | 1 |
| University of Colorado, Denver | 1 |
| Distribuidora Biolife SA de CV | 1 |
| National Neuroscience Institute | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| German University in Cairo | 1 |
| UConn Health | 1 |
| University of Ostrava | 1 |
| Rutgers, The State University of New Jersey | 1 |
| University of California, Davis | 1 |
| Alto Neuroscience | 1 |
| Aelis Farma | 1 |
| University of Alabama at Birmingham | 1 |
| [GE Healthcare](https://specstream.ai/data/clinical-trials/company/ge-healthcare) | 1 |
| University of Virginia | 1 |
| University of Oklahoma | 1 |
| NeuroBiogen Co., Ltd | 1 |
| Zaparackas and Knepper LTD | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 32 |
| Canada | 3 |
| Italy | 3 |
| China | 3 |
| South Korea | 2 |
| Norway | 2 |
| Taiwan | 2 |
| Mexico | 1 |
| Singapore | 1 |
| Egypt | 1 |
| Czechia | 1 |
| Israel | 1 |
| France | 1 |
| Spain | 1 |
| Portugal | 1 |
| Sweden | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Junk removal companies in the United States](https://specstream.ai/data/businesses/junk-removal-companies/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
